Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric Adenocarcinoma
This study is a phase II study, to evaluate the effectiveness and safety of Camrelizumab combined with apatinib for advanced gastric or esophagogastric adenocarcinoma progressed after immune checkpoint inhibitors.
Advanced Gastric Carcinoma
DRUG: camrelizumab|DRUG: Apatinib Mesylate
Objective response rate(ORR), ORR was defined as the percentage of participants with best overall response of either CR or PR, up to 1 years
Progression-Free Survival(PFS), PFS was defined as the time from the first day of treatment to the first documented disease progression per RECIST 1.1 based on investigator assessment, or death due to any cause, whichever occurs first., up to 2 years|Overall Survival (OS), OS was defined as the first day of treatment to death due to any cause., up to 2.5 years|Disease control rate(DCR), DCR was defined as the percentage of participants with best overall response of either CR or PR or SD, up to 1 years|Time to progression(TTP), TTP was defined as the time from the first day of treatment to the first documented disease progression per RECIST 1.1 based on investigator assessment in All Participants., up to 2years|Duration of response(DOR), DOR was defined as the time from first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first., up to 2years
This study is a phase II study, to evaluate the effectiveness and safety of Camrelizumab combined with apatinib for advanced gastric or esophagogastric adenocarcinoma progressed after immune checkpoint inhibitors.